Stock-Based Compensation (Details) (USD $)	3 Months Ended		6 Months Ended			6 Months Ended	1 Months Ended	3 Months Ended	5 Months Ended	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014 RSAs	Jun. 30, 2014 RSAs Performance-contingent	May 31, 2014 RSAs Performance-contingent 2011 Restricted Stock Awards	Mar. 31, 2014 RSAs Performance-contingent 2011 Restricted Stock Awards	May 31, 2014 RSAs Performance-contingent 2011 Restricted Stock Awards	Dec. 31, 2011 RSAs Performance-contingent 2011 Restricted Stock Awards	Jun. 30, 2014 2012 Equity Incentive Plan
Stock-based compensation
Shares remaining available for issuance											2,533,778
Period for which compensation committee has approved grants						3 years
Shares of common stock approved and authorized for issuance										1,290,000
Timeframe for achievement of performance conditions										6 years
Maximum potential expense, net of forfeiture					$ 19,500,000
Stock-based compensation expense	7,747,000	7,162,000	21,281,000	13,257,000				6,800,000	7,000,000
Total stock-based compensation that will be recognized in the year								7,000,000
Remaining potential stock-based compensation expense after modification						24,500,000
Stock-based compensation expenses expected to be recognized by either reporting entity or Theravance Biopharma							$ 10,700,000
Vesting period							12 months